Publicaciones en colaboración con investigadores/as de Universidad de Sevilla (25)

2009

  1. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis

    Gut, Vol. 58, Núm. 7, pp. 929-939

  2. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells

    Arthritis and Rheumatism, Vol. 60, Núm. 4, pp. 1006-1019

2008

  1. Emergence of cortistatin as a new immunomodulatory factor with therapeutic potential in immune disorders

    Molecular and Cellular Endocrinology, Vol. 286, Núm. 1-2, pp. 135-140

  2. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: Altered expression and signal in immune cells

    Arthritis and Rheumatism, Vol. 58, Núm. 4, pp. 1010-1019

  3. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis

    Arthritis and Rheumatism, Vol. 58, Núm. 4, pp. 1026-1037

  4. Vasoactive intestinal peptide protects against β-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels

    GLIA, Vol. 56, Núm. 10, pp. 1091-1103

2007

  1. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?

    Trends in Pharmacological Sciences, Vol. 28, Núm. 9, pp. 482-491

  2. Emerging roles of vasoactive intestinal peptide: A new approach for autoimmune therapy

    Annals of the Rheumatic Diseases

  3. Regulation of immune tolerance by anti-inflammatory neuropeptides

    Nature Reviews Immunology, Vol. 7, Núm. 1, pp. 52-63

  4. Tuning immune tolerance with vasoactive intestinal peptide: A new therapeutic approach for immune disorders

    Peptides, Vol. 28, Núm. 9, pp. 1833-1846

  5. Tuning inflammation with anti-inflammatory neuropeptides

    Expert Opinion on Biological Therapy, Vol. 7, Núm. 4, pp. 461-478

  6. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis

    Trends in Molecular Medicine, Vol. 13, Núm. 6, pp. 241-251

2006

  1. Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice

    Annals of the New York Academy of Sciences

  2. Therapeutic Treatment of Experimental Colitis With Regulatory Dendritic Cells Generated With Vasoactive Intestinal Peptide

    Gastroenterology, Vol. 131, Núm. 6, pp. 1799-1811

2005

  1. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, Núm. 38, pp. 13562-13567

2004

  1. The many faces of VIP in neuroimmunology: A cytokine rather a neuropeptide?

    FASEB Journal, Vol. 18, Núm. 12, pp. 1325-1334

  2. The significance of vasoactive intestinal peptide in immunomodulation

    Pharmacological Reviews, Vol. 56, Núm. 2, pp. 249-290

2000

  1. Immunobiology of vasoactive intestinal peptide (VIP)

    Immunology Today

1999

  1. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: In vitro and in vivo studies

    Journal of Immunology, Vol. 162, Núm. 4, pp. 2358-2367

1998

  1. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: In vitro and in vivo studies

    Journal of Neuroimmunology, Vol. 85, Núm. 2, pp. 155-167